Zoetis (NYSE:ZTS) Cut to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen downgraded Zoetis from a "buy" to a "hold", while other firms' views vary (Weiss cut to "sell", Citi and BTIG remain bullish), leaving a consensus rating of Hold and an average target price of $151.75.
• Zoetis beat Q results with $1.48 EPS versus $1.40 expected and $2.39B in revenue versus $2.36B, and set FY2026 guidance of $7.00–$7.10 EPS (analysts expect ~7.02).
• The stock opened at $114.22 (12‑month range $112.97–$172.23), with a market cap of $48.05B and a P/E of 18.97, trading materially below the average analyst target.

Zoetis (NYSE:ZTS - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report issued on Saturday.

A number of other brokerages also recently commented on ZTS. Weiss Ratings downgraded shares of Zoetis from a "hold (c-)" rating to a "sell (d+)" rating in a report on Friday, March 27th. Citigroup began coverage on shares of Zoetis in a report on Wednesday, April 15th. They set a "buy" rating and a $145.00 price target for the company. BTIG Research restated a "buy" rating and issued a $160.00 target price on shares of Zoetis in a report on Thursday, February 26th. UBS Group lowered their target price on shares of Zoetis from $136.00 to $130.00 and set a "neutral" rating for the company in a report on Tuesday. Finally, Bank of America boosted their target price on shares of Zoetis from $135.00 to $140.00 and gave the company a "neutral" rating in a report on Friday, February 13th. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Zoetis has a consensus rating of "Hold" and an average target price of $151.75.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $114.22 on Friday. The company has a market cap of $48.05 billion, a PE ratio of 18.97, a price-to-earnings-growth ratio of 1.77 and a beta of 0.87. Zoetis has a 12 month low of $112.97 and a 12 month high of $172.23. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The company has a 50-day simple moving average of $119.93 and a 200-day simple moving average of $124.79.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. The business had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company's quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities analysts anticipate that Zoetis will post 7.02 earnings per share for the current year.

Institutional Investors Weigh In On Zoetis

Several institutional investors have recently bought and sold shares of ZTS. Brighton Jones LLC raised its position in Zoetis by 180.4% in the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock valued at $754,000 after purchasing an additional 2,978 shares during the period. Empowered Funds LLC raised its position in Zoetis by 6.2% in the first quarter. Empowered Funds LLC now owns 11,293 shares of the company's stock valued at $1,859,000 after purchasing an additional 657 shares during the period. Intech Investment Management LLC raised its position in Zoetis by 17.2% in the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company's stock valued at $1,374,000 after purchasing an additional 1,224 shares during the period. Sivia Capital Partners LLC raised its position in Zoetis by 73.8% in the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company's stock valued at $522,000 after purchasing an additional 1,422 shares during the period. Finally, Glenview Trust co raised its position in Zoetis by 11.8% in the second quarter. Glenview Trust co now owns 4,780 shares of the company's stock valued at $745,000 after purchasing an additional 506 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.